↓ Skip to main content

Dove Medical Press

Article Metrics

Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia

Overview of attention for article published in International Journal of Nanomedicine, April 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
29 Mendeley
Title
Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
Published in
International Journal of Nanomedicine, April 2015
DOI 10.2147/ijn.s55796
Pubmed ID
Authors

Louis Pelus, Jonathan Hoggatt, Tiffany Tate

Abstract

Chemotherapy, irradiation, and other agents are widely used to target the process of cell division in neoplastic cells. However, while these therapies are effective against most cancers, the high proliferative rate of the cells of the hematopoietic system that produce billions of blood cells needed daily throughout life is extremely sensitive to these agents, resulting in loss of blood cell populations, which can be life threatening. Neutropenia is the most serious hematologic toxicity of chemotherapy, which can result in patient morbidity and mortality due to opportunistic infection and often is the limiting factor in dose escalation or duration of chemotherapeutic administration. Neutropenic patients often require hospitalization and incur substantial medical costs associated with anti-infective therapy. Treatment of iatrogenic and congenic neutropenia was changed in the early 1990s with the introduction of filgrastim (Neupogen(®)) and pegfilgrastim (Neulasta(®)). With the expiration of patent lives of both of these drugs, biosimilars have begun to emerge. In this review, we will summarize the chemical characteristics, pharmacokinetics, safety and efficacy of lipegfilgrastim (Lonquex(®)), the first long-acting biosimilar filgrastim to receive regulatory approval and enter the marketplace.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 29 100%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 6 21%
Student > Bachelor 4 14%
Researcher 4 14%
Student > Master 4 14%
Student > Doctoral Student 2 7%
Other 7 24%
Unknown 2 7%
Readers by discipline Count As %
Medicine and Dentistry 8 28%
Pharmacology, Toxicology and Pharmaceutical Science 7 24%
Biochemistry, Genetics and Molecular Biology 3 10%
Unspecified 2 7%
Agricultural and Biological Sciences 2 7%
Other 3 10%
Unknown 4 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 April 2015.
All research outputs
#20,268,102
of 22,799,071 outputs
Outputs from International Journal of Nanomedicine
#3,324
of 3,814 outputs
Outputs of similar age
#224,057
of 264,674 outputs
Outputs of similar age from International Journal of Nanomedicine
#72
of 82 outputs
Altmetric has tracked 22,799,071 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,814 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,674 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 82 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.